title: [Treatment of acromegaly].
abstract: Growth hormone (GH) hypersecretion leads to acromegaly which is associated with several co-morbidities and increased mortality. Despite of the typical clinical features and modern diagnostic tools, it often takes years from the onset of the disease until the diagnosis. The aims of the treatment are to reduce or control the tumor growth, inhibit the GH hypersecretion, normalize the insulin-like growth factor-I (IGF-I) levels, treat the co-morbidities and therefore reduce mortality. There are three approaches for therapy: surgery, medical management (dopamine agonist, somatostatin analogues and GH receptor antagonist), and radiotherapy. Efficient therapy of the disease is based on the appropriate multidisciplinary team management.
authors: HM Allami Egészségügyi Központ II. Belgyógyászati Osztály, Endokrin Szakprofil, Budapest.
authors: Judit
authors: J
authors: Dénes
authors: Márta
authors: M
authors: Korbonits
authors: Erika
authors: E
authors: Hubina
authors: Miklós
authors: M
authors: Góth
mesh_terms: D000172:Acromegaly / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000378:metabolism / Q000628:therapy; D019382:Human Growth Hormone / Q000378:metabolism; D006801:Humans; D033183:Interdisciplinary Communication; D010348:Patient Care Team; D010911:Pituitary Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D011954:Receptors, Dopamine / Q000187:drug effects; D011986:Receptors, Somatotropin / Q000819:agonists; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D011954:Receptors, Dopamine; D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; D013004:Somatostatin